The goal of this single-center prospective randomized controlled trial is to test and compare the safety and effectiveness of autologous blood transfusion in spinal surgery for lung cancer spinal metastases. The main questions it aims to answer are:
* Does autologous blood transfusion increase the incidence of new metastases? * Does autologous blood transfusion affect postoperative hemoglobin levels and the number of circulating tumor cells in the blood? * Can autologous blood transfusion reduce the rate of allogeneic transfusion during and after surgery for spinal metastases?
The age range is 18-75 years old;
The pathological diagnosis was lung cancer and spinal metastatic tumor;
Expected survival > 3 months, can tolerate surgery;
Unstable spine; And/or spinal cord nerve compression, nerve function; Progressive decline, palliative spinal open decompression surgery
Serious heart dysfunction or heart failure, diagnosed blood system diseases, coagulation disorders;
Severe renal insufficiency or need hemodialysis treatment;
Sepsis or septicemia;
Unable to obtain consent from the patient or family.